DHA sent the attached letter raising concerns with HS 1 for HB 383 as currently written. While HB 383 rightly prohibits discrimination against 340B drug distribution by manufacturers and third-party logistics providers, and prohibits discrimination by pharmacy benefits managers against 340B covered entities, House Substitute 1 removes hospitals from the benefit of this bill. 

Click here to read the letter.